How can we mitigate treatment-associated morbidity in patients with germ cell tumors?

References

• Stephenson A, Eggener SE, Bass EB, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. 2019;202(2):272–281.
   PubMed Web of Science ®Google Scholar
• Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054–1068.
   PubMed Web of Science ®Google Scholar
• Skoogh J, Steineck G, Cavallin-Ståhl E, et al. Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. Int J Androl. 2011;34(2):183–192.
   PubMedGoogle Scholar
• Jacobs LA, Vaughn DJ. Hypogonadism and infertility in testicular cancer survivors. J Natl Compr Cancer Netw JNCCN. 2012;10(4):558–563.
   PubMed Web of Science ®Google Scholar
• Clifford TG, Burg ML, Hu B, et al. Satisfaction with testicular prosthesis after radical orchiectomy. Urology. 2018;114:128–132.
   PubMed Web of Science ®Google Scholar
• Yossepowitch O, Aviv D, Wainchwaig L, et al. Testicular prostheses for testis cancer survivors: patient perspectives and predictors of long-term satisfaction. J Urol. 2011;186(6):2249–2252.
   PubMed Web of Science ®Google Scholar
• Brydøy M, Fosså SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005;97(21):1580–1588.
   PubMedGoogle Scholar
• Nichols CR, Roth B, Albers P, et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(28):3490–3493.
   PubMed Web of Science ®Google Scholar
• Chertack N, Ghandour RA, Singla N, et al. Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. Cancer. 2020;126(19):4362–4370.
   PubMed Web of Science ®Google Scholar
• Hoehn RS, Wima K, Vestal MA, et al. Effect of hospital safety-net burden on cost and outcomes after surgery. JAMA Surg. 2016;151(2):120–128.
   PubMed Web of Science ®Google Scholar
• Agrawal V, Dinh PC, Fung C, et al. Adverse health outcomes among US testicular cancer survivors after cisplatin-based chemotherapy vs surgical management. JNCI Cancer Spectr. 2020;4(2):pkz079. .
   PubMed Web of Science ®Google Scholar
• Watson RA, De La Peña H, Tsakok MT, et al. Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. Br J Cancer. 2018;119(9):1044–1051.
   PubMed Web of Science ®Google Scholar
• Roncolato FT, Chatfield M, Houghton B, et al. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Intern Med J. 2016;46(8):893–898.
   PubMed Web of Science ®Google Scholar
• Shamash J, Sarker S-J, Huddart R, et al. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Ann Oncol. 2017;28(6):1333–1338.
   PubMed Web of Science ®Google Scholar
• Gugic J, Zaletel LZ, Oblak I. Treatment-related cardiovascular toxicity in long-term survivors of testicular cancer. Radiol Oncol. 2016;51(2):221–227.
   PubMed Web of Science ®Google Scholar
• Fung C, Fossa SD, Beard CJ, et al. Second malignant neoplasms in testicular cancer survivors. J Natl Compr Cancer Netw JNCCN. 2012;10(4):545–556.
   PubMed Web of Science ®Google Scholar
• Suarez-Ibarrola R, Abufaraj M, Shariat SF. Intermediate and long-term complications associated with adjuvant chemotherapy for stage I germ cell tumor patients. Curr Opin Urol. 2018;28(5):485–490.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger CK, Nappi L, Nichols C. Management of stage II germ cell tumors: be sure, be patient, be safe. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(22):1856–1862.
   PubMed Web of Science ®Google Scholar
• Subramanian VS, Nguyen CT, Stephenson AJ, et al. Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol. 2010;28(5):504–509.
   PubMed Web of Science ®Google Scholar
• Pettus JA, Carver BS, Masterson T, et al. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology. 2009;73(2):328–331;discussion 331–332.
   Web of Science ®Google Scholar
• Albers P, Hiester A, Grosse Siemer R, et al. PRIMETEST trial: interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment. J Clin Oncol. 2019;37(7_suppl):507.
   Web of Science ®Google Scholar
• Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(6):1101–1106.
   PubMed Web of Science ®Google Scholar
• Voorhoeve PM, Le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124(6):1169–1181.
   PubMed Web of Science ®Google Scholar
• Gillis AJM, Stoop HJ, Hersmus R, et al. High-throughput microRNAome analysis in human germ cell tumours. J Pathol. 2007;213(3):319–328.
   PubMed Web of Science ®Google Scholar
• Palmer RD, Murray MJ, Saini HK, et al. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 2010;70(7):2911–2923.
   PubMed Web of Science ®Google Scholar
• Nappi L, Thi M, Lum A, et al. Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(33):3090–3098.
   PubMed Web of Science ®Google Scholar
• Lafin JT, Singla N, Woldu SL, et al. Serum MicroRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection. Eur Urol. 2020;77(2):290–292.
   PubMed Web of Science ®Google Scholar